HIV/AIDS Therapy
New HIV/AIDS therapy research from F. Tomaka et al outlined
Published in AIDS Weekly, May 4th, 2009
Data detailed in 'Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers' have been presented. According to recent research from the United States, "Darunavir (TMC114) is a new HIV protease inhibitor (PI). This Phase I, randomized, open-label trial compared the effects of darunavir plus low-dose ritonavir (RTV) (darunavir/RTV) with those of atazanavir/RTV on lipid and glucose parameters."
"Forty-nine HIV-negative, healthy male volunteers received RTV 100 mg once a day (qd) for 7 days, followed by either darunavir/RTV 800/100 mg qd (n=25) or atazanavir/RTV 300/100 mg qd (n=24) for 21...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2009-05-04)
More Articles from AIDS Weekly
- BioMed Central
Rifampin kinetics poor in children - Infectious Diseases Society of America
Has HIV become more virulent? - Abscess
Studies by V.N. Lopez and co-authors describe new findings in abscess - Angiology
Researchers from Vrije University Amsterdam detail findings in angiology - Cancer Vaccines
Reports from Baylor College of Medicine, College of Medicine describe recent advances in cancer vaccines - Drug Delivery
New drug delivery study findings have been reported by Y.G. Jin and co-researchers - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
